SCHEDULE 13G: Sio Capital Management Discloses Significant Stake in Bright Minds Biosciences

Sio Capital Management, LLC has reported a 7.21% beneficial ownership stake in Bright Minds Biosciences Inc., holding 507,562 common shares as of March 31, 2025.

Summary

• Sio Capital Management, LLC, a Delaware-based registered investment adviser, has filed a Schedule 13G indicating beneficial ownership in Bright Minds Biosciences Inc.
• As of March 31, 2025, Sio Capital Management beneficially owned 507,562 common shares of Bright Minds Biosciences Inc.
• This ownership represents 7.21% of the issuer's common shares outstanding.
• The percentage is calculated based on 7,043,989 common shares outstanding as of January 31, 2025, as disclosed in Bright Minds Biosciences Inc.'s Prospectus on February 14, 2025.
• Sio Capital Management holds shared voting power and shared dispositive power over all 507,562 shares.
• Michael Castor, who controls Sio Capital Management, LLC and Sio GP, LLC, may be deemed to control the voting and dispositive decisions for these shares, though beneficial ownership is expressly disclaimed for purposes of Section 13(d) of the Exchange Act.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in tone. The acquisition of a significant stake by an investment adviser can be seen as a positive signal, but the filing itself does not contain subjective language or performance metrics.

Positives

• The disclosure of a significant stake by an investment adviser like Sio Capital Management can be viewed as a vote of confidence in Bright Minds Biosciences Inc. by a professional investor.

Negatives

• This filing is a disclosure of ownership and does not inherently contain negative financial or operational information about the issuer.

Risks

• The filing itself does not detail specific risks related to Bright Minds Biosciences Inc.'s operations or financial health. It primarily concerns the ownership structure of a significant shareholder.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from Bright Minds Biosciences Inc. or Sio Capital Management, LLC regarding the issuer's future performance or strategic direction.

Management Comments

• Jin W. Lee, Chief Compliance Officer of Sio Capital Management, LLC, certified that 'to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This filing is a standard disclosure under SEC regulations, indicating that an institutional investor, Sio Capital Management, has acquired a significant passive stake (over 5%) in Bright Minds Biosciences Inc. Such disclosures provide transparency into major ownership positions within publicly traded companies, which can signal investor interest in the biotechnology or pharmaceutical sector, where Bright Minds Biosciences likely operates given its name.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may increase confidence and potentially attract further investment, signaling a positive outlook from a professional fund.
• Management: Awareness of a significant shareholder may influence strategic decisions, though Sio Capital Management has certified its passive intent.

Key Dates

Keywords

Bright Minds Biosciences Inc., Sio Capital Management, Schedule 13G, Beneficial Ownership, Common Shares, Investment Adviser, SEC Filing, Equity Stake, Institutional Investor